Navigation Links
HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
Date:5/5/2011

FRAMINGHAM, Mass. and SYDNEY, May 5, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenues of $18.0 million for the first quarter ended March 31, 2011.  This represents a 68 percent increase from $10.7 million in revenues for the first quarter of 2010.

"During the first quarter, we generated our second highest international sales results for the HeartWare® Ventricular Assist System.  We are appreciative of the strong support of our 56 customers in 18 countries, as 134 pumps were sold outside of the U.S.," explained Doug Godshall, President and Chief Executive Officer.  "The international markets accounted for 65 percent of our revenues, or approximately $11.7 million for the 2011 first quarter, up from $8.0 million in the first quarter of 2010."

"In the U.S., where first quarter revenues more than doubled to $6.3 million compared to $2.7 million in the first quarter of 2010, we now have 46 of the planned 50 U.S. sites approved for implantation in our 450-patient destination therapy study, and 121 patients have been randomized and enrolled," added Mr. Godshall.  "In the first quarter, we also received our largest allotment – 94 patients – granted by the Food and Drug Administration (FDA) in January under the Continued Access Protocol (CAP) for our bridge-to-transplant clinical study.  Participating hospital sites began the re-initiation process and have enrolled 28 patients in this third CAP cohort."

Total operating expenses for the first quarter of 2011 were $18.0 million, compared to $9.3 million in the prior year period.  Research and development expense was $9.3 million for the first quarter of 2011, primari
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... 25, 2011 Omthera Pharmaceuticals, Inc., a privately-held emerging ... has joined the Company as Vice President of Quality. ... Operating Officer, Drs. Ben Machielse, Mr. Maines will be ...   Mr. Maines brings to the Company ...
... 2011 GlaxoSmithKline, one of the world,s leading ... 10 winners of its GlaxoSmithKline IMPACT Awards. In ... organizations will receive $400,000 in grant funding for ... their communities. Three of the North ...
Cached Medicine Technology:Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 3
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based ... practice and med-spa with the addition of new Silk ... cosmetic treatments and services. , “Silk Peel is a ... Dr. Ho. “As a result it can address issues ... spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Today, Yunx.co.uk, ... of evening dresses and other special occasion outfits, ... new models are offered at discounted prices, up to ... the young ladies with their fashionable designs, gorgeous looks ... no exception. The business is devoted to designing and ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company offering ... company announces its multiple layer bamboo panel board ... new products. , Bamboo panel is the product made ... bamboo panel board features high quality selective bamboo and ... The bamboo panel consists of multiple layers of bamboo. ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Hepatitis C infection ... according to a new study. Treatment advances have made ... but many develop memory and thinking problems, mood swings and ... authors said. It,s believed that long-term infections with other ... may affect the brain. One of the prime suspects has ...
(Date:12/24/2014)... (HealthDay News) -- Researchers say they have used human ... eggs and sperm. While this had already been ... time that these types of cells -- called primordial ... stem cells, according to the team at the University ... germ cells is one of the earliest events during ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2
... EAGAN, Minn., Feb. 9 Blue Cross and Blue Shield of Minnesota ... manager of the largest database of vendored disease management programs. The awards ... reducing adverse health events for its members. Blue Cross, disease management efforts ... diabetes , ...
... Equips Participants with Tools to Live Healthy, Active LivesCLEVELAND, ... Clinic has consistently sought to shift the national focus ... part of this commitment , Cleveland Clinic has ... helps reverse and decrease the effects of several common ...
... boosts well-being, study suggests, , , MONDAY, Feb. 9 (HealthDay ... buy happiness, purchasing life experiences instead of material possessions ... a study that asked more than 150 older college ... them happy, researchers found that people were more satisfied ...
... the Top Achievements in 50 Years of Women,s Health RARITAN, ... globulin product, celebrates its 40th year in the marketplace helping ... Newborn (HDN). In 1968, a new mother at Holy ... initial recipient of the world,s first injectable treatment to prevent ...
... intended to prevent HIV infection in women has demonstrated ... in Africa and the United States. Findings of the ... Allergy and Infectious Diseases (NIAID), part of the NIH, ... Opportunistic Infections in Montreal. , The study investigators ...
... Cancer Research Center have discovered a mechanism in liver metabolism ... in severe metabolic disorders. Mice suffering from metabolic syndrome or ... called LSR in the liver, as reported by researchers headed ... As a result, only small amounts of fat are ...
Cached Medicine News:Health News:Blue Cross Receives Disease Management Awards 2Health News:Blue Cross Receives Disease Management Awards 3Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 2Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 3Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 4Health News:Experiences Bring More Joy Than Possessions Do 2Health News:Experiences Bring More Joy Than Possessions Do 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 2Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 4Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 5Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 6Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 7Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 8Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 9Health News:Anti-HIV gel shows promise in large-scale study in women 2Health News:Anti-HIV gel shows promise in large-scale study in women 3Health News:Anti-HIV gel shows promise in large-scale study in women 4Health News:Pathologically elevated blood fat levels in obesity: Researchers discover molecular causes 2
Medium clip size, 10mm...
... in 10mm and 5mm sizes. Our market-leading ... placement., ,The LIGACLIP ERCA Endoscopic Rotating ... patient use instrument designed to provide a ... The instrument delivers 20 titanium clips that ...
... utilizes turbidimetric immunoassay methodology which is a ... of 0.2-28.0 mg/dL. This assay is homogeneous, ... clinical chemistry analyzers. The Wako CRP-HS assay ... linearity, correlation, and sensitivity. Expected values are ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: